^
    Back
    Association details:
    Biomarker:FH mutation
    Cancer:Renal Cell Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Ann Transl Med
    Title:

    Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data

    Published date:
    09/04/2020
    Excerpt:
    One patient with a germline FH mutation was diagnosed with hereditary leiomyomatosis RCC. He was treated with bevacizumab and erlotinib combination and showed a durable response.
    DOI:
    10.21037/atm-20-3466